JHS Svendgaard Laboratories Q4 FY24 Share Price & Earnings Call Analysis
- Market cap
- ₹70 Cr
- ROE
- -1.17%
- Price to sales
- 0.64
- Debt to equity
- 0.09
- 52W high / low
- ₹13.2 / ₹6.55
- Sales growth (5Y)
- 0.18%
- EBITDA margin
- 2.77%
- Net profit margin
- -2.01%
- Promoter holding
- 33.85%
- Sales (last year)
- ₹109 Cr
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of oral and dental products for national and international brands[1]
Guidance scorecard · Q4 FY24 call
What JHS Sven.Lab.'s management guided
and where it ranks in Personal Products
RevenueQ4 FY24 call
20–40%- JHS Svendgaard expects a 30% to 40% increase in revenue for FY25 compared to FY23-24.
- Growth to be driven by both organic expansion (new customers like Unilever, Amway, Reliance, Zydus) and inorganic acquisitions in broader personal care segments.
- Capacity utilization targeted to increase from current 30-35% to 70-80% over the next two years without major new capex except for customer-specific moulds.
- Increased sales volumes anticipated especially as Reliance's general trade oral care business ramps up.
- Export sales, which dropped during COVID to 1-2% of sales, are recovering with improved terms and margins.
2 more points from JHS Sven.Lab.'s call on revenue
Create a free account to keep reading this call
MarginsQ4 FY24 call
Up 2%+See what JHS Sven.Lab. said on margins — free account, 30 seconds.
CapexQ4 FY24 call
Planned- Existing production capacity is around 30-35% utilization, targeted to ramp up to 70-80% in the next two years without significant new capex.
- Some capex is required for new product categories beyond oral care, primarily for packaging lines due to varying packaging needs (pouches, bottles, pumps).
- The company is actively looking at acquisitions (not mergers) and is confident of undertaking a substantial acquisition in the current financial year using existing cash and possibly stock.
- No new merger plans currently after the Vedic merger did not materialize, with focus shifted to acquisitions instead.
FundraisingQ4 FY24 call
See what JHS Sven.Lab. said on fundraising — free account, 30 seconds.
Order bookQ4 FY24 call
Rising- The current firm order book for JHS Svendgaard Laboratories Limited stands at approximately INR 110 crores for the financial year 2024-25.
- The company expects to start executing these orders from Q1 of the current financial year.
- Management expressed confidence in improving this order book size in the coming months.
- There is a clear focus on ramping up capacity utilization from the current 30-35% to about 70-80% over the next two years, which would support higher order execution without major new capex.
2 more points from JHS Sven.Lab.'s call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Personal Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹2,041 Cr | 61.0 | |
| 2 | 40%+ | Flat | ₹400 Cr | 35.6 | |
| 3 | Honasa Consumer Ltd | 20–40% | Up 0–2% | ₹14,745 Cr | 58.4 |
| 4 | 10–20% | Flat | ₹87,493 Cr | 42.1 | |
| 5 | 10–20% | Flat | ₹68,298 Cr | 34.4 | |
| 6 | 10–20% | Flat | ₹16,419 Cr | 21.7 |
Sign up free to see every company in the sector ranking and track JHS Sven.Lab..
Pro shows every company guiding 40%+ revenue growth →Full Personal Products rankingFinancials of JHS Sven.Lab.
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of JHS Sven.Lab.
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 | 23.27 | 32.70 |
| Expenses + | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 | 21.60 | 34.34 |
| Operating Profit | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 | 1.67 | -1.64 |
| OPM % | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% | 4.08% | 7.18% | -5.02% |
| Other Income + | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 | 1.14 | 0.59 | 0.73 |
| Interest | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.20 | 0.28 | 0.22 |
| Depreciation | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 | 1.90 | 1.86 |
| Profit before tax | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 | 0.08 | -2.99 |
| Tax % | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% | 1,800.00% | -887.50% | 19.73% |
| Net Profit + | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.20 | 0.79 | -3.57 |
| EPS in Rs | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 | 0.09 | -0.41 |
Financials of JHS Sven.Lab.
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 102 |
| Expenses + | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 99 |
| Operating Profit | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | 3 |
| OPM % | -7% | 7% | 11% | 10% | 0% | 1% | 2% | -1% | -11% | -1% | -4% | 3% |
| Other Income + | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 |
| Profit before tax | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -2 |
| Tax % | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4,000% | -24% | 18% | 58% | -16% |
| Net Profit + | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -2 |
| EPS in Rs | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of JHS Sven.Lab.
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 87 |
| Reserves | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 | 87 |
| Borrowings + | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 | 15 |
| Other Liabilities + | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 | 26 |
| Total Liabilities | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
| Fixed Assets + | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | 89 |
| CWIP | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 | 4 |
| Investments | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 | 5 |
| Other Assets + | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 | 117 |
| Total Assets | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
Financials of JHS Sven.Lab.
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 7 | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 | |
| Cash from Investing Activity + | 1 | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 | |
| Cash from Financing Activity + | -10 | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 | |
| Net Cash Flow | -1 | 2 | 3 | 0 | -5 | -0 | 20 | -16 | 32 | -28 | -2 | |
| Free Cash Flow | 9 | -7 | -17 | 3 | -26 | 0 | 5 | -16 | 21 | -33 | -14 | |
| CFO/OP | -189% | -58% | -33% | 119% | -10,000% | 595% | 650% | 1,051% | -257% | 1,001% | 122% |
Financials of JHS Sven.Lab.
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory Days | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 | 85 |
| Days Payable | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 | 100 |
| Cash Conversion Cycle | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 | 45 |
| Working Capital Days | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 | 42 |
| ROCE % | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% | -1% |
Continue your research
What JHS Sven.Lab.'s management said in earlier quarters
Others in Personal Products this season
- Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
- Recode Studios Ltd (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
- Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
- Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag